Nerve growth factor receptor limits inflammation to promote remodeling and repair of osteoarthritic joints.
Lan ZhaoYumei LaiHongli JiaoJian HuangPublished in: Nature communications (2024)
Osteoarthritis (OA) is a painful, incurable disease affecting over 500 million people. Recent clinical trials of the nerve growth factor (NGF) inhibitors in OA patients have suggested adverse effects of NGF inhibition on joint structure. Here we report that nerve growth factor receptor (NGFR) is upregulated in skeletal cells during OA and plays an essential role in the remodeling and repair of osteoarthritic joints. Specifically, NGFR is expressed in osteochondral cells but not in skeletal progenitor cells and induced by TNFα to attenuate NF-κB activation, maintaining proper BMP-SMAD1 signaling and suppressing RANKL expression in mice. NGFR deficiency hyper-activates NF-κB in murine osteoarthritic joints, which impairs bone formation and enhances bone resorption as exemplified by a reduction in subchondral bone and osteophytes. In human OA cartilage, NGFR is also negatively associated with NF-κB activation. Together, this study suggests a role of NGFR in limiting inflammation for repair of diseased skeletal tissues.
Keyphrases
- growth factor
- signaling pathway
- induced apoptosis
- oxidative stress
- knee osteoarthritis
- cell cycle arrest
- lps induced
- pi k akt
- clinical trial
- nuclear factor
- end stage renal disease
- rheumatoid arthritis
- endothelial cells
- epithelial mesenchymal transition
- ejection fraction
- bone mineral density
- newly diagnosed
- bone regeneration
- chronic kidney disease
- peripheral nerve
- poor prognosis
- gene expression
- mesenchymal stem cells
- prognostic factors
- type diabetes
- binding protein
- toll like receptor
- cell death
- immune response
- skeletal muscle
- open label
- long non coding rna
- insulin resistance
- study protocol
- transforming growth factor
- patient reported
- phase ii